Benzinga | Aug 9, 2021 04:30PM EDT

Regenxbio Q2 EPS $(1.36) Misses $(1.12) Estimate, Sales $22.00M Miss $29.02M Estimate

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.12) by 21.43 percent. This is a 49.45 percent decrease over losses of $(0.91) per share from the same period last year. The company reported quarterly sales of $22.00 million which missed the analyst consensus estimate of $29.02 million by 24.19 percent. This is a 32.80 percent increase over sales of $16.57 million the same period last year.